TGF-β downregulates CAIII expression via MAPK and PI3K signaling pathways in colon carcinoma and osteosarcoma cells

Abstract

Identification of cancer-associated genes is critical for developing effective treatments of colorectal cancer (CRC). A limited number of studies have examined the mechanisms and genes underlying CRC. Abnormal transforming growth factor beta (TGF-β) expression was observed at different stages of carcinoma. We examined the effect of cancer-related cytokine TGF-β on carbonic anhydrase (CA) III gene expression in colon cancer HT-29 cells. TGF-β (500 U/mL) downregulated CAIII gene expression at both the mRNA and protein levels. Transient transfection experiments indicated that different CAIII promoter constructs were active in HT-29 cells. TGF-β reduced transcriptional activity of all promoter constructs, indicating that the potential response element for TGF-β-directed transcription lies within the-108/+86 region of the CAIII promoter. According to the non-Smad pathway inhibitory assay, TGF-β downregulated the CAIII gene through mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) and phosphoinositide-3-kinase (PI3K) pathways. The same decreasing effect was determined in the Saos-2, osteosarcoma cell line, indicating that the effect of TGF-β on CAIII was not tissue-specific. However, examination of PI3K and MAPK/ERK signaling pathways with suitable inhibitors revealed that the PI3K but not the MAPK/ERK pathway was responsible for TGF-β downregulation.

Transcriptional activation of Carbonic Anhydrase III (CAIII) mediated by SP1

“…HIF1-α directly binds on to Hypoxia response elements in CAIII promoter [29]. Moreover, in our different study, in colon cancer cells, TGF-beta inhibited the CAIII gene via the phosphoinositide-3-kinase (PI3K) and mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) pathways [42]. Thus, there is virtually no information of transcriptional regulation of CAIII in normal oxygen condition.…”